Omrix Crosseal Promotions Lack Proper Risk Info, CBER “Warning Letter” States
This article was originally published in The Pink Sheet Daily
Executive Summary
Displaying the package insert near a violative convention panel for the fibrin sealant Crosseal is not sufficient to meet risk disclosure requirements, the letter states. Omrix is developing a corrective action plan with FDA.